SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
OmniAb, Inc. Common Stock
OABI
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
Last trade$5.01
Day change+$0.12 (+2.45%)
Day range$4.75 – $5.03
Volume758,206
Market cap$713M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$713.26M
Price / earnings
—
Price / book
2.86×
Price / sales
17.74×
EV / sales
17.17×
EV / EBITDA
-27.77×
Profitability
Earnings per share
-$0.30
Return on assets
-14.94%
Return on equity
-17.45%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
4.21×
Quick ratio
4.21×
Cash ratio
1.36×
Cash flow
Price / cash flow
267.54×
Price / free cash flow
299.69×
Free cash flow
$2.38M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for OABI, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$3.99M
$13.42M
$14.43M
$8.38M
$2.24M
$3.9M
$4.15M
$10.8M
Cost of revenue
$309K
$610K
$15K
$9K
$29K
$262K
$3K
$0
Gross profit
$3.68M
$12.81M
$14.41M
$8.37M
$2.21M
$3.64M
$4.15M
$10.8M
Selling, general and administrative
$7.24M
$6.65M
$6.62M
$6.84M
$6.78M
$7.68M
$7.92M
$7.36M
Research and development
$9.55M
$9.59M
$9.64M
$13.91M
$10.38M
$10.86M
$12.6M
$13.31M
Total operating expenses
$20.05M
$19.44M
$22.24M
$23.98M
$20.35M
$19.85M
$23M
$26.73M
Operating income
-$16.37M
-$6.64M
-$7.83M
-$15.61M
-$18.14M
-$16.22M
-$18.84M
-$15.92M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$15.86M
-$6.21M
-$7.27M
-$14.55M
-$17.69M
-$15.76M
-$18.31M
-$15.22M
Income taxes
-$127K
-$353K
$442K
-$367K
-$1.16M
$119K
-$106K
-$2.16M
Net income
-$15.73M
-$5.86M
-$7.71M
-$14.18M
-$16.53M
-$15.88M
-$18.2M
-$13.07M
Net income attributable to common shareholders
-$15.73M
-$5.86M
-$7.71M
-$14.18M
-$16.53M
-$15.88M
-$18.2M
-$13.07M
EBITDA
-$12.76M
-$3.01M
-$1.2M
-$7.9M
-$14.05M
-$12.13M
-$14.65M
-$8.32M
Basic earnings per share
-$0.12
-$0.05
-$0.06
-$0.11
-$0.14
-$0.15
-$0.17
-$0.12
Diluted earnings per share
-$0.12
-$0.05
-$0.06
-$0.11
-$0.14
-$0.15
-$0.17
-$0.12
Recent news
Company coverage with links to the original publishers.
OmniAb, Inc. (OABI) reported a quarterly loss of $0.12 per share matching consensus estimates, with revenues of $3.99 million exceeding expectations by 10.12%. The company has outperformed the S&P 500 by 182.7% year-to-date. However, the stock received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market. The Medical-Drugs industry ranks in the top 36% of Zacks industries.
OmniAb, Inc. (OABI) has been upgraded to a Zacks Rank #2 (Buy) rating due to upward trends in earnings estimates. The company's consensus estimate for fiscal year 2026 shows no year-over-year change at -$0.35 per share, but analysts have raised estimates by 10.3% over the past three months. The upgrade positions the stock in the top 20% of Zacks-covered stocks, suggesting potential near-term price appreciation.
The article compares AbbVie and Eli Lilly as pharmaceutical investment options for 2026. AbbVie focuses on immunology and neuroscience with revenue of $61.2B and faces patent expiration risks, while Eli Lilly is experiencing explosive 45% revenue growth driven by its GLP-1 drugs (Mounjaro and Zepbound) with projected 2026 revenue of $85.2B. Despite Eli Lilly's higher valuation, the article recommends it for long-term investors due to the sustained demand and lifecycle nature of its metabolic therapies.
VERAXA Biotech announced substantial progress in its pipeline and partnering strategy, with plans to focus investments on its BiTAC platform for T cell engagers and antibody-drug conjugates. The company aims to have its lead BiTAC-TCE candidate VXA-102 IND/CTA-ready by early 2028 and intends to monetize non-BiTAC assets to finance growth. The company is actively pursuing partnerships and reported strong industry interest in its novel BiTAC technology.
AI is transforming healthcare through innovative technologies like disease screening, genetic testing, antibody discovery, and drug development platforms, with several companies making significant technological advancements in medical AI applications.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.